Therefore, in many types of cancers the CD8+/Treg ratio has been widely used as an immune score that represents the tumor microenvironment and that has proven to be very efficient in-patient prognosis and to predict the response to neoadjuvant chemotherapy [19,20]. The gene discussed is CD8A; the disease is cancer.